PCM
CBIO icon

Prelude Capital Management’s Crescent Biopharma CBIO Stock Holding History

Prelude Capital Management’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-201
Closed -$239K – 1827
2019
Q2 		$239K Buy
201
+25
+14% +$29.9K 0.01% 680
2019
Q1 		$219K Buy
176
+174
+8,700% +$199K 0.01% 687
2018
Q4 		$2K Sell
2
-3
-60% -$3.61K ﹤0.01% 1685
2018
Q3 		$8K Buy
5
+2
+67% +$3.02K ﹤0.01% 1523
2018
Q2 		$5K Buy
+3
New +$5.16K ﹤0.01% 1556

Other funds holding CBIO

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return

Prelude Capital Management's CBIO Position: Q3 2019 in Review

Prelude Capital Management sold out of Crescent Biopharma (CBIO) in Q3 2019, closing a stake of 201 shares — an estimated $239K sold.

Prelude Capital Management first reported a position in CBIO in Q2 2018 and held it in 5 quarters. The position peaked at $239K in Q2 2019. 75 funds tracked by Wall St. Rank hold CBIO as of Q3 2019.

  • Prelude Capital Management reported no remaining Crescent Biopharma position as of Q3 2019 after selling out during the quarter.
  • Prelude Capital Management sold 201 Crescent Biopharma shares in Q3 2019, an estimated $239K.
  • Prelude Capital Management first reported a position in Crescent Biopharma in Q2 2018 and held it in 5 quarters.
  • Prelude Capital Management's Crescent Biopharma position peaked at $239K in Q2 2019.
  • 75 funds tracked by Wall St. Rank held Crescent Biopharma as of Q3 2019.

Based on Prelude Capital Management's 13F filing for Q3 2019, filed 14 Nov 2019.